These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36715485)

  • 1. Hybrid continuous reassessment method with overdose control for safer dose escalation.
    Ghosh D; Xie H; Zhang L; Chen F; Mohanty S; Li X
    J Biopharm Stat; 2023 Sep; 33(5):586-595. PubMed ID: 36715485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hybrid design for dose-finding oncology clinical trials.
    Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
    Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
    Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
    Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.
    Yan F; Mandrekar SJ; Yuan Y
    Clin Cancer Res; 2017 Aug; 23(15):3994-4003. PubMed ID: 28546227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
    Zhou H; Yuan Y; Nie L
    Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
    Ji Y; Wang SJ
    J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian hybrid dose-finding design in phase I oncology clinical trials.
    Yuan Y; Yin G
    Stat Med; 2011 Jul; 30(17):2098-108. PubMed ID: 21365672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies.
    Zhang H; Chiang AY; Wang J
    Stat Med; 2022 Nov; 41(27):5463-5483. PubMed ID: 35428037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between continuous and discrete doses for model based designs in cancer dose finding.
    Diniz MA; Tighiouart M; Rogatko A
    PLoS One; 2019; 14(1):e0210139. PubMed ID: 30625194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
    Zhang Y; Kutner M; Chen Z
    Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonparametric overdose control with late-onset toxicity in phase I clinical trials.
    Lin R; Yin G
    Biostatistics; 2017 Jan; 18(1):180-194. PubMed ID: 27549121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
    Li P; Liu R; Lin J; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving safety of the continual reassessment method via a modified allocation rule.
    Mozgunov P; Jaki T
    Stat Med; 2020 Mar; 39(7):906-922. PubMed ID: 31859399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keyboard design for phase I drug-combination trials.
    Pan H; Lin R; Zhou Y; Yuan Y
    Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
    McGovern A; Chapple AG; Ma C
    Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating historical information to improve phase I clinical trials.
    Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
    Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.